A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, Sarah Danson et al.|Journal of Clinical Oncology|2019Cited by 31
Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Cancer Research|2024Cited by 3
Abstract CT136: NUC-7738, a novel ProTide transformation of 3′-deoxyadenosine, in patients with advanced solid tumorsRuth Plummer, Sarah P. Blagden, Farasat Kazmi et al.|Cancer Research|2021Cited by 2
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 studySarah P. Blagden, Elizabeth Ruth Plummer, Stefan N. Symeonides et al.|Molecular Cancer Therapeutics|2023Cited by 1
566TiP A first-in-human study of NUC-7738, a ProTide transformation of 3’-deoxyadenosine, in patients with advanced solid tumours (NuTide:701)Sarah P. Blagden, Ruth Plummer, Noor Md Haris et al.|Annals of Oncology|2021Cited by 0